Hypothesis: Platelet-Rich Plasma as an Adjunct Therapy for Eczema Targeting Inflammation, Skin Barrier Repair, and Chronic Recurrence

This review explores the complex factors involved in alopecia areata, such as immune and genetic influences, and discusses advances in diagnostic and therapeutic approaches, while reporting no new clinical results.

Two L-PRP treatments improve hair density in mild to moderate alopecia.

This review found that platelet-rich plasma may have a positive effect on scarring alopecia by slowing progression and reducing inflammation, though evidence remains limited to case reports.

This review discusses the mechanisms and potential benefits of platelet-rich plasma therapy for various skin conditions and reports no new clinical findings.

This study found that platelet-rich plasma microneedles promoted hair regrowth in mice by facilitating angiogenesis and cell proliferation, showing promise for a minimally invasive hair regeneration treatment.

This review suggests that platelet-rich plasma may be a promising treatment for immune-mediated alopecias, including alopecia areata and primary cicatricial alopecias, but definitive recommendations are limited due to insufficient high-quality evidence.

This study found that platelet-rich plasma treatment led to significant reductions in lesion sizes for both plaque psoriasis and atopic dermatitis, with many patients achieving complete remission and no adverse events reported.

This study found that two sessions of platelet-rich plasma mesotherapy significantly improved symptoms in patients with corticosteroid-induced rosacea-like dermatitis without further treatment.

This study found that platelet-rich plasma had limited efficacy in treating alopecia areata but may help restore immune balance in the affected areas.

This study summarizes how the IL-23/IL-17 axis contributes to inflammatory skin diseases like psoriasis and highlights that biologics targeting this pathway, including monoclonal antibodies against IL-23 and IL-17, have shown efficacy in clinical trials for these conditions.